EMMPRIN confers metabolic advantage for monocytes and macrophages to promote disease in a model of multiple sclerosis
D. K. Kaushik, A. Das, C. Silva, C. D’Mello, L. G. N. Almeida, S. Patel, D. Bennin, N. Ghasemi, P. Neri, Antoine Dufour, N. J. Bahlis, M. Xue, V. W. Yong
This study shows that EMMPRIN promotes pro-inflammatory metabolism in monocytes/macrophages, worsening multiple sclerosis, and its deletion reduces disease severity.
Journal of Neuroinflammation · Aug 15, 2026Peer-reviewedImmunology